The board of directors of The United Laboratories International Holdings Limited announced that on 15 June 2023, the application for the clinical trial of class 1 innovative new drug UBT251 Injection self-developed
by The United Bio-Technology (Hengqin) Co. Ltd., a wholly-owned subsidiary of the Company, on indications of adult type 2 diabetes, weight management and nonalcoholic fatty liver/nonalcoholic steatohepatitis ("NASH") obtained the acceptance and payment notices by China National Medical Products Administration. At present, the Company is the first enterprise in China and the second enterprise in the world to apply for the clinical trial of a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) prepared by chemical synthesis peptide. UBT251 is a long-acting polypeptide drug that stimulates triple-target receptors for GLP-1/GIP /GCG simultaneously. By acting on GLP-1 receptors, GIP receptors and GCG receptors, UBT251 promotes insulin secretion, regulates appetite and energy metabolism, reduces blood glucose and weight, and improves liver steatosis. Preclinical studies in various animal models have proven that UBT251 significantly reduces blood glucose and weight, improves liver steatosis and fibrosis, and that it outperforms the marketed single-target GLP-1 receptor drug Semaglutide and the dual-target GLP-1/GIP drug Tirzepatide in the in-vivo treatment of model animals. The product is expected to be beneficial for the treatment of patients with various metabolic disorders such as type 2 diabetes, overweight/obesity and NASH, when administered once a week by subcutaneous injection. At present, the fastest progress in the R&D of the same target drugs, both domestic and abroad, has just announced the initiation of phase III clinical trials. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.